Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Reply to N. Singh et al.

Pérol M, Pérol D, Chouaid C.

J Clin Oncol. 2013 Mar 20;31(9):1251-2. No abstract available.

PMID:
23616988
2.

Lack of improvement in overall survival with gemcitabine/ erlotinib maintenance and its relationship with pemetrexed use in the second-line setting.

Singh N, Goyal A.

J Clin Oncol. 2013 Mar 20;31(9):1250-1. doi: 10.1200/JCO.2012.47.4817. Epub 2013 Feb 4. No abstract available.

PMID:
23382469
3.

Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.

Pérol M, Chouaid C, Pérol D, Barlési F, Gervais R, Westeel V, Crequit J, Léna H, Vergnenègre A, Zalcman G, Monnet I, Le Caer H, Fournel P, Falchero L, Poudenx M, Vaylet F, Ségura-Ferlay C, Devouassoux-Shisheboran M, Taron M, Milleron B.

J Clin Oncol. 2012 Oct 1;30(28):3516-24. Epub 2012 Sep 4.

PMID:
22949150
4.

Management of non-small cell lung cancer: focus on erlotinib. Foreword.

Cappuzzo F.

Drugs. 2012 Jun 19;72 Suppl 1:1-2. doi: 10.2165/1163029-S0-000000000-00000. No abstract available.

PMID:
22712791
5.

Gefitinib and cisplatin-based chemotherapy in non-small-cell lung cancer: simply a bad combination?

Normanno N.

J Clin Oncol. 2005 Feb 1;23(4):928-30; author reply 930-1. No abstract available.

PMID:
15681550
7.

Potential interaction of chemotherapy and gefitinib in the induction of hematologic neoplasia.

Ravindranathan M, Klementich FJ, Jones DV Jr.

Leukemia. 2007 Dec;21(12):2546-7. Epub 2007 Jul 26. No abstract available.

PMID:
17657221
8.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica.

Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.

PMID:
22285168
9.

Second-line erlotinib for non-small-cell lung cancer.

Lorusso V, Cinieri S.

Lancet Oncol. 2012 Apr;13(4):e141-2; author reply e142. doi: 10.1016/S1470-2045(12)70113-4. Epub 2012 Mar 30. No abstract available.

PMID:
22469123
10.

Gefitinib plus docetaxel in non-small-cell lung cancer.

Zalcman G, Bergot E.

Lancet. 2009 Feb 14;373(9663):541; author reply 542. doi: 10.1016/S0140-6736(09)60192-6. No abstract available.

PMID:
19217981
11.

Beyond first-line NSCLC therapy: chemotherapy or erlotinib?

Paz-Ares L.

Lancet Oncol. 2012 Mar;13(3):225-7. doi: 10.1016/S1470-2045(12)70001-3. Epub 2012 Jan 24. No abstract available.

PMID:
22277836
12.

Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non-Small Cell Lung Cancer Patient.

Remon J, Gazzah A, Besse B, Soria JC.

J Thorac Oncol. 2015 Aug;10(8):e72-3. doi: 10.1097/JTO.0000000000000561. No abstract available.

13.

27th ESMO Congress, Nice, 18-22 October 2002. Iressa disappoints in NSCLC.

[No authors listed]

Eur J Cancer. 2003 Jan;39(1):1. No abstract available.

PMID:
12585281
14.

Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.

Higgins B, Kolinsky K, Smith M, Beck G, Rashed M, Adames V, Linn M, Wheeldon E, Gand L, Birnboeck H, Hoffmann G.

Anticancer Drugs. 2004 Jun;15(5):503-12.

PMID:
15166626
15.

Role of induction chemotherapy in resectable N2 non-small cell lung cancer.

de Marinis F, Tedesco B, Treggiari S, De Santis S, Cipri A, Belli R, Condò S, Ariganello O, Di Molfetta M, Migliorino MR.

J Thorac Oncol. 2007 May;2(5 Suppl):S31-4. Review. No abstract available.

16.

Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer.

Mok TS, Wu YL, Yu CJ, Zhou C, Chen YM, Zhang L, Ignacio J, Liao M, Srimuninnimit V, Boyer MJ, Chua-Tan M, Sriuranpong V, Sudoyo AW, Jin K, Johnston M, Chui W, Lee JS.

J Clin Oncol. 2009 Oct 20;27(30):5080-7. doi: 10.1200/JCO.2008.21.5541. Epub 2009 Sep 8.

PMID:
19738125
17.

[New era in cancer therapy. Gefitinib: small molecule--strong action].

Arnheim K.

MMW Fortschr Med. 2004 Nov 18;146(47):70-1. German. No abstract available.

PMID:
15624666
18.

[Medical therapy of elderly patients with advanced non-small cell lung carcinoma: significance and possibilities].

Gridelli C.

Suppl Tumori. 2004 Mar-Apr;3(2):S36-7. Review. Italian. No abstract available.

PMID:
15067964
19.

[Maintenance treatment of non-small cell lung cancer].

Hansen O, Schytte T.

Ugeskr Laeger. 2010 Mar 22;172(12):954. Danish. No abstract available.

PMID:
20334788
20.

EGFR inhibitors for wild-type EGFR NSCLC: to use or not to use?

Jassem J, Dziadziuszko R.

Lancet Oncol. 2013 Sep;14(10):916-7. doi: 10.1016/S1470-2045(13)70352-8. Epub 2013 Jul 22. No abstract available.

PMID:
23883923

Supplemental Content

Support Center